


PHARMACEUTICAL 2022



Orgenesis Inc. Rank 217 of 475







PHARMACEUTICAL 2022



Orgenesis Inc. Rank 217 of 475

The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 270% points. The greatest weakness of Orgenesis Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -79%, being 198% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	25,758
Cost of Goods Sold	0
Intangible Assets	20,224
Liabilities, Current	15,365
Liabilities, Non-Current	5,845
Other Assets	3,588
Other Compr. Net Income	-535
Other Expenses	1,056
Other Liabilities	0
Other Net Income	-3,429
Property and Equipment	10,271
Research and Development	36,644
Revenues	37,780
Selling, General and Administrative Expense	14,710

Output Variable	Value in 1000 USD
Assets	59,841
Liabilities	21,210
Expenses	52,410
Stockholders Equity	38,631
Net Income	-18,059
Comprehensive Net Income	-18,326
Economic Capital Ratio	-79%

